Circulating Lipoproteins: A Trojan Horse Guiding Squalenoylated Drugs to LDL-Accumulating Cancer Cells.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Sobot, DunjaMura, Simona
Rouquette, Marie
Vukosavljevic, Branko
Cayre, Fanny
Buchy, Eric
Pieters, Grégory
Garcia-Argote, Sébastien
Windbergs, Maike
Desmaële, Didier
Couvreur, Patrick
Issue Date
2017-07-05
Metadata
Show full item recordAbstract
Selective delivery of anticancer drugs to rapidly growing cancercells can be achieved by taking advantage of their high receptor-mediated uptake of low-density lipoproteins (LDLs). Indeed, wehave recently discovered that nanoparticles made of the squa-lene derivative of the anticancer agent gemcitabine (SQGem)strongly interacted with the LDLs in the human blood. In thepresent study, we showed both in vitro and in vivo that suchinteraction led to the preferential accumulation of SQGem incancer cells (MDA-MB-231) with high LDL receptor expression.As a result, an improved pharmacological activity has beenobserved in MDA-MB-231 tumor-bearing mice, an experi-mental model with a low sensitivity to gemcitabine. Accord-ingly, we proved that the use of squalene moieties not onlyinduced the gemcitabine insertion into lipoproteins, but thatit could also be exploited to indirectly target cancer cells in vivo.PubMed ID
28606375Type
ArticleISSN
1525-0024ae974a485f413a2113503eed53cd6c53
10.1016/j.ymthe.2017.05.016
Scopus Count
The following license files are associated with this item:
- Creative Commons
Related articles
- Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug delivery.
- Authors: Sobot D, Mura S, Yesylevskyy SO, Dalbin L, Cayre F, Bort G, Mougin J, Desmaële D, Lepetre-Mouelhi S, Pieters G, Andreiuk B, Klymchenko AS, Paul JL, Ramseyer C, Couvreur P
- Issue date: 2017 May 30
- Low-Density Lipoproteins and Human Serum Albumin as Carriers of Squalenoylated Drugs: Insights from Molecular Simulations.
- Authors: Yesylevskyy SO, Ramseyer C, Savenko M, Mura S, Couvreur P
- Issue date: 2018 Feb 5
- Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics.
- Authors: Arias JL, Reddy LH, Othman M, Gillet B, Desmaële D, Zouhiri F, Dosio F, Gref R, Couvreur P
- Issue date: 2011 Feb 22
- Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor.
- Authors: Reddy LH, Renoir JM, Marsaud V, Lepetre-Mouelhi S, Desmaële D, Couvreur P
- Issue date: 2009 Sep-Oct
- Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
- Authors: Maksimenko A, Caron J, Mougin J, Desmaële D, Couvreur P
- Issue date: 2015 Mar 30